Johnson & Johnson Gets $265 Price Target From Leerink

Leerink Partners analyst David Risinger upgraded Johnson & Johnson from hold to buy and set a $265 price target. JNJ closed Friday at $234.34 after rising 1.13%.
JNJ1.06%
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned